Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Pandemic telehealth flexibilities for buprenorphine treatment: A synthesis of evidence and policy implications for expanding opioid use disorder care in the U.S

Noa Krawczyk, Bianca D. Rivera, Carla King, Bridget C.E. Dooling
doi: https://doi.org/10.1101/2023.03.16.23287373
Noa Krawczyk
1Center for Opioid Epidemiology and Policy (COEP), Department of Population Health, NYU Grossman School of Medicine, New York NY
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Noa.krawczyk@nyulangone.org
Bianca D. Rivera
1Center for Opioid Epidemiology and Policy (COEP), Department of Population Health, NYU Grossman School of Medicine, New York NY
MPH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carla King
1Center for Opioid Epidemiology and Policy (COEP), Department of Population Health, NYU Grossman School of Medicine, New York NY
MPH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bridget C.E. Dooling
2Regulatory Studies Center, The George Washington University, Washington, D.C
JD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Buprenorphine is a highly effective treatment for opioid use disorder and a critical tool for addressing the worsening U.S. overdose crisis. However, multiple barriers to treatment - including stringent federal regulations - have historically made this medication hard to reach for many who need it. In 2020, under the COVID-19 Public Health Emergency, federal regulators substantially changed access to buprenorphine by allowing prescribers to initiate patients on buprenorphine via telehealth without first evaluating them in person. As the Public Health Emergency is set to expire in May of 2023, Congress and federal agencies can leverage extensive evidence from studies conducted during the wake of the pandemic to make evidencebased decisions on the regulation of buprenorphine going forward. To aid policy makers, this review synthesizes and interprets peer-reviewed research on the effect of buprenorphine flexibilities on uptake and implementation of telehealth, and its impact on OUD patient and prescriber experiences, access to treatment and health outcomes. Overall, our review finds that many prescribers and patients took advantage of telehealth, including the audio-only option, with a wide range of benefits and few downsides. As a result, federal regulators—including agencies and Congress—should continue non-restricted use of telehealth for buprenorphine initiation.

Competing Interest Statement

Noa Krawczyk provides expert testimony for ongoing opioid litigation

Funding Statement

This work was supported by a grant from the Pew Charitable Trusts. Noa Krawczyk was additionally supported by a grant from the National Institute On Drug Abuse of the National Institutes of Health under Award Number K01DA055758. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data Availability

This is a synthesis of research studies so all studies are available in peer-reviewed paper databases

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted March 17, 2023.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Pandemic telehealth flexibilities for buprenorphine treatment: A synthesis of evidence and policy implications for expanding opioid use disorder care in the U.S
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Pandemic telehealth flexibilities for buprenorphine treatment: A synthesis of evidence and policy implications for expanding opioid use disorder care in the U.S
Noa Krawczyk, Bianca D. Rivera, Carla King, Bridget C.E. Dooling
medRxiv 2023.03.16.23287373; doi: https://doi.org/10.1101/2023.03.16.23287373
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Pandemic telehealth flexibilities for buprenorphine treatment: A synthesis of evidence and policy implications for expanding opioid use disorder care in the U.S
Noa Krawczyk, Bianca D. Rivera, Carla King, Bridget C.E. Dooling
medRxiv 2023.03.16.23287373; doi: https://doi.org/10.1101/2023.03.16.23287373

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Health Policy
Subject Areas
All Articles
  • Addiction Medicine (270)
  • Allergy and Immunology (552)
  • Anesthesia (135)
  • Cardiovascular Medicine (1757)
  • Dentistry and Oral Medicine (238)
  • Dermatology (173)
  • Emergency Medicine (312)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (658)
  • Epidemiology (10796)
  • Forensic Medicine (8)
  • Gastroenterology (589)
  • Genetic and Genomic Medicine (2947)
  • Geriatric Medicine (287)
  • Health Economics (534)
  • Health Informatics (1927)
  • Health Policy (836)
  • Health Systems and Quality Improvement (745)
  • Hematology (291)
  • HIV/AIDS (630)
  • Infectious Diseases (except HIV/AIDS) (12515)
  • Intensive Care and Critical Care Medicine (688)
  • Medical Education (299)
  • Medical Ethics (86)
  • Nephrology (324)
  • Neurology (2798)
  • Nursing (151)
  • Nutrition (433)
  • Obstetrics and Gynecology (559)
  • Occupational and Environmental Health (597)
  • Oncology (1463)
  • Ophthalmology (444)
  • Orthopedics (172)
  • Otolaryngology (255)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (380)
  • Pediatrics (866)
  • Pharmacology and Therapeutics (366)
  • Primary Care Research (337)
  • Psychiatry and Clinical Psychology (2639)
  • Public and Global Health (5364)
  • Radiology and Imaging (1011)
  • Rehabilitation Medicine and Physical Therapy (595)
  • Respiratory Medicine (726)
  • Rheumatology (330)
  • Sexual and Reproductive Health (289)
  • Sports Medicine (279)
  • Surgery (327)
  • Toxicology (47)
  • Transplantation (150)
  • Urology (125)